Public limited company · Oslo
NYKODE THERAPEUTICS ASA
ActiveResearch and experimental development on natural sciences and engineering (72.100)
The life line 2006–2026
Operating revenue per year, with recorded events above. As a table
Operating revenue 2025: USD 453k.
Sources: the Register of Company Accounts (company accounts), fetched 15 Nov 2026; the Brønnøysund Register Centre. Each event has the colour of the section it is in.
In brief
NYKODE THERAPEUTICS ASA is a public limited company in Oslo, founded in 2006, in the industry research and experimental development on natural sciences and engineering. The chief executive is Michael Thyrring Engsig, and the chair of the board is Barbara Helene Hannelore Krebs-Pohl. In 2025 the company had USD 453k in operating revenue and a net profit of USD −12.7m; the group had revenue of USD 453k. The largest owner is RASMUSSENGRUPPEN AS with 9.2%.
Put together by Intelligo from the sections below; each figure stands with its source where it belongs.
Overview
§ 01 Latest changes
4 changes, latest 13 Nov 2026
- Number of employees 48 → 47
- Number of employees 47 → 48
- Changed capital 326546444 → 391546444
- Changed capital 3265464.44 → 3915464.44
Source: the Brønnøysund Register Centre and Intelligo's own observations, fetched 15 Nov 2026 · All events →
Overview
§ 02 Worth knowing
2 points
- NoteOperating loss three years running, 2023–2025
- OKEquity ratio 92.5%, above the industry median
Assumed: derived by Intelligo by fixed rules, not a credit rating. How we calculate
Overview
§ 03 Key figures
Revenue USD 453k in 2025
Revenue
USD 453k
−95.1% from 2024
20232025
Operating profit
USD −29.2m
+36.3% from 2024
20232025
Net profit
USD −12.7m
+67.1% from 2024
20232025
Equity
USD 95.0m
−32.2% from 2024
20232025
Source: the Register of Company Accounts, read 15 Nov 2026 · The full accounts →
Finances
§ 04 Where the money comes from and goes
Financial year 2025
Of every krone of operating revenue in 2025:
- Wages and social costs 2,018%
- Depreciation 402%
- Other operating costs 4,117%
Costs exceeded revenue: the operating result was USD −29.2m.
Source: the Register of Company Accounts via areg.no, read 15 Nov 2026
Finances
§ 05 Financial health
Equity ratio 92.5%
- NYKODE THERAPEUTICS ASA, 2025
- Industry median, assumed: −4.4% · 48.9% · +3.0%
Equity USD 95.0m92% of the assets (USD 102.7m)
Source: the Register of Company Accounts, read 15 Nov 2026. The median is derived by Intelligo from 694 companies in 72.100 Research and experimental development on natural sciences and engineering, not stated by the source.
Finances
§ 06 Accounts
6 years, latest 2025
| USD 1,000 | 2023–25 | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Operating revenue | 453 | 9,158 | 13,362 | |
| Operating profit | −29,162 | −45,748 | −56,480 | |
| Profit before tax | −18,174 | −45,201 | −42,429 | |
| Net profit | −12,673 | −38,479 | −33,392 | |
| Total assets | 102,717 | 156,082 | 210,353 | |
| Equity | 94,977 | 140,142 | 174,832 | |
| Liabilities | 7,740 | 15,940 | 35,521 |
Source: the Register of Company Accounts, read 15 Nov 2026 · All 6 years →
Management and ownership
§ 07 Officers
8 officers now
- DELOITTE ASAuditor since 2007
- AMESTO ACCOUNTHOUSE ASAccountant
- Michael Thyrring EngsigChief executive since 2019
- Barbara Helene Hannelore Krebs-PohlChair of the board since 2026
- Christian ÅbyholmBoard member since 2020
- Susanne StuffersBoard member since 2019
Source: the Brønnøysund Register Centre, read 23 Oct 2026 · All 8 roles, former ones too →
Management and ownership
§ 08 Signature, procuration and authorisations
To styremedlemmer i fellesskap.
May sign for the company:
To styremedlemmer i fellesskap.
Procuration: none registered.
The board has 1 authorisation in force now: capital increase, until 30 Jun 2027.
The signature is word for word from the register. Source: the Register of Business Enterprises, read 24 Aug 2026
Management and ownership
§ 09 Owners
1,002 shareholders · largest 9.2%
| Owner | Share |
|---|---|
| RASMUSSENGRUPPEN AS | 9.2% |
| DATUM OPPORTUNITY AS | 8.0% |
| VICTORIA INDIA FUND AS | 5.4% |
| 999 others | 77.4% |
Source: the Tax Administration's Register of Shareholders as of 31 December 2025, read 31 Jul 2026 · All 1,002 owners →
Management and ownership
§ 10 Group
Group accounts 2025
NYKODE THERAPEUTICS ASA files group accounts; the subsidiaries are not in the Register of Shareholders.
The group 2025: operating revenue USD 453k (−95.1%).
Source: the Register of Company Accounts, read 15 Nov 2026 · The whole group →
Management and ownership
§ 11 Portfolio
None registered
No holdings registered.The shareholder register has no shares held by the company. Checked 15 Nov 2026.
Management and ownership
§ 12 Network
19 connections
- Person
- Company
4 people link NYKODE THERAPEUTICS ASA to 16 other companies: Christian Åbyholm 8, Susanne Stuffers 4, Trygve Lauvdal 3 and Michael Thyrring Engsig 1.
Source: the Brønnøysund Register Centre, read 23 Oct 2026 · Explore the network →
Events and registers
§ 13 Events
148 since 2015
Events per year
20152026
Since 2015: 183 announcements, 8 register changes and 3 new and 0 former owners. Most happened in 2020 and 2021.
Source: the announcements of the Brønnøysund Register Centre, the Tax Administration's Register of Shareholders, Doffin, TED and NAV, read 1 Nov 2026. Register changes are Intelligo's own observations. · All 148 events →
Events and registers
§ 14 Notices
183, latest 31 Aug 2026
- Kapital
- Vedtektsdato
- Fullmakt kapitalforhøyelse
Source: The Brønnøysund Register Centre's announcements ↗, read 1 Nov 2026 · All 183 →
Events and registers
§ 15 Charges
Not fetched yet
Events and registers
§ 16 Other registers
Found in 3 of 7
- The Central Coordinating RegisterRegistered 13 Jan 2007
- VATRegistered
- The Register of Business EnterprisesRegistered 13 Jan 2007
- The Cleaning RegisterNot registered
- The Register of Staffing AgenciesNot registered
- Smiley scheme, the Norwegian Food Safety AuthorityNot registered
- The Financial Supervisory Authority's licence registerNot registered
Purpose: Utvikling av biomedisinske produkter og tjenester. Formålet kan fremmes ved deltagelse i eller samarbeid med andre foretak i inn- og utland eller rådgivende virksomhet.
Source: the Brønnøysund Register Centre, the Labour Inspection Authority, the Food Safety Authority and the Financial Supervisory Authority, each on its own, fetched 15 Nov 2026
Market
§ 17 Tenders
None registered
No tenders recorded.No public tenders won, lost or announced, in Doffin or TED. Checked 15 Nov 2026.
Market
§ 18 Vacancies
None registered
No vacancies.No open ads at NAV. Checked 15 Nov 2026.
Market
§ 19 Competitors
Industry code 72.100
The companies most like it:
Compare themThe selection is Intelligo's, not stated by the source: companies met in tenders and winners of tenders of the same kind, otherwise the same industry code, nearest in place and size. Source: the Brønnøysund Register Centre, Doffin and TED, fetched 15 Nov 2026 · All competitors → · Largest in the industry →
Last
§ 20 Questions and answers
7 questions
- Who is the chief executive of NYKODE THERAPEUTICS ASA?
Michael Thyrring Engsig, since 2019. § 07 - Who owns NYKODE THERAPEUTICS ASA?
1,002 shareholders. The largest is RASMUSSENGRUPPEN AS with 9.2%, DATUM OPPORTUNITY AS with 8.0% and VICTORIA INDIA FUND AS with 5.4%. § 09 - What was the revenue in 2025?
USD 453k in the company and USD 453k in the group. § 06 - Who can sign for NYKODE THERAPEUTICS ASA?
To styremedlemmer i fellesskap. § 08 - Who is the auditor?
DELOITTE AS, from 13 Jan 2007. § 07 - Where is NYKODE THERAPEUTICS ASA based?
Gaustadalléen 21, 0349 Oslo. - When was NYKODE THERAPEUTICS ASA founded?
22 Nov 2006, registered in the Register of Business Enterprises 13 Jan 2007. § 16
The answers come from the sections linked to, with their sources.